These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 8815427)

  • 1. Effectiveness of deferiprone (L1) releasing the aluminum bound to plasma proteins in chronic renal failure.
    Canteros-Piccotto MA; Fernández-Martín JL; Cannata-Ortiz MJ; Cannata-Andía JB
    Nephrol Dial Transplant; 1996 Jul; 11(7):1488-9. PubMed ID: 8815427
    [No Abstract]   [Full Text] [Related]  

  • 2. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1).
    Fernández-Martín JL; Menéndez-Fraga P; Canteros MA; Díaz-López JB; Cannata-Andía JB
    Clin Chim Acta; 1994 Oct; 230(2):137-45. PubMed ID: 7834865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Barr J; Baillod RA
    Arzneimittelforschung; 1994 Apr; 44(4):522-6. PubMed ID: 8011008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FTIR study of protective action of deferoxamine and deferiprone on the kidney tissues of aluminum loaded mice.
    Sivakumar S; Khatiwada CP; Sivasubramanian J; Raja B
    Spectrochim Acta A Mol Biomol Spectrosc; 2014 Jan; 118():488-97. PubMed ID: 24080580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators.
    Kontoghiorghes GJ
    Arch Toxicol Suppl; 1996; 18():202-14. PubMed ID: 8678796
    [No Abstract]   [Full Text] [Related]  

  • 6. FT-Raman study of deferoxamine and deferiprone exhibits potent amelioration of structural changes in the liver tissues of mice due to aluminum exposure.
    Sivakumar S; Khatiwada CP; Sivasubramanian J; Raja B
    Spectrochim Acta A Mol Biomol Spectrosc; 2014 Jan; 118():461-9. PubMed ID: 24080577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dialysis fluids as a source of aluminum accumulation.
    Savory J; Wills MR
    Contrib Nephrol; 1984; 38():12-23. PubMed ID: 6713889
    [No Abstract]   [Full Text] [Related]  

  • 8. Chelation of aluminum by combining deferasirox and deferiprone in rats.
    Saljooghi AS
    Toxicol Ind Health; 2012 Sep; 28(8):740-5. PubMed ID: 22025507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the protective activity of deferiprone, an aluminum chelator, on aluminum-induced developmental toxicity in mice.
    Albina ML; Bellés M; Sanchez DJ; Domingo JL
    Teratology; 2000 Aug; 62(2):86-92. PubMed ID: 10931505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of deferiprone on tissues aluminum removal and copper, zinc, manganese level in rabbits.
    Liu P; Yao YN; Wu SD; Dong HJ; Feng GC; Yuan XY
    J Inorg Biochem; 2005 Aug; 99(8):1733-7. PubMed ID: 16045992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein binding of aluminium in normal subjects and in patients with chronic renal failure.
    Rahman H; Channon SM; Skillen AW; Ward MK; Kerr DN
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():360-5. PubMed ID: 3991523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aluminum, zinc and copper concentrations in plasma in chronic renal insufficiency.
    Zumkley H; Bertram HP; Lison A; Knoll O; Losse H
    Clin Nephrol; 1979 Jul; 12(1):18-21. PubMed ID: 477052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum aluminum concentration and the deferoxamine test in a group of patients under chronic hemodialysis].
    de Sousa FT; Barbas JM; dos Santos JP; Mil-Homens MC; Aniceto JP; Melo JA; Rosário EM; Fonseca AP; Vizela MH
    Acta Med Port; 1986; 7(4):161-4. PubMed ID: 3825604
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum concentrations of aluminum in hemodialysis patients.
    Sandhu G; Djebali D; Bansal A; Chan G; Smith SD
    Am J Kidney Dis; 2011 Mar; 57(3):523-5. PubMed ID: 21257246
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
    Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
    [No Abstract]   [Full Text] [Related]  

  • 16. What is the value of plasma/serum aluminum in patients with chronic renal failure?
    Winney RJ; Cowie JF; Robson JS
    Clin Nephrol; 1985; 24 Suppl 1():S2-8. PubMed ID: 3842104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The binding of chloramphenicol to serum proteins in patients with chronic renal insufficiency.
    Grafnetterová J; Vodrázka Z; Jandová D; Schück O; Tomásek R; Lachmanová J
    Clin Nephrol; 1976 Oct; 6(4):448-50. PubMed ID: 975643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypercalcemia and hyperaluminemia in children with chronic renal insufficiency].
    Hinojosa-Lezama M; Gordillo-Paniagua G; Muñoz-Arizpe R; Mercado-Polo L
    Bol Med Hosp Infant Mex; 1987 Sep; 44(9):535-9. PubMed ID: 3663320
    [No Abstract]   [Full Text] [Related]  

  • 19. Aluminum kinetics in patients treated with hemodialysis or hemofiltration with sorbent recycling of ultrafiltrate.
    Shapiro WB; Schilb TP; Porush JG
    Trans Am Soc Artif Intern Organs; 1984; 30():342-6. PubMed ID: 6533906
    [No Abstract]   [Full Text] [Related]  

  • 20. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.